Toll Free: 1-888-928-9744

Parkinson's Disease - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 879 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Parkinson's Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Pipeline Review, H2 2016, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson's disease. Parkinson's disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 30, 37, 5, 173, 42 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 1, 50, 15 and 1 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 Introduction 10 Parkinson's Disease Overview 11 Therapeutics Development 12 Parkinson's Disease - Therapeutics under Development by Companies 14 Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes 30 Parkinson's Disease - Pipeline Products Glance 33 Parkinson's Disease - Products under Development by Companies 37 Parkinson's Disease - Products under Investigation by Universities/Institutes 56 Parkinson's Disease - Companies Involved in Therapeutics Development 60 Parkinson's Disease - Therapeutics Assessment 245 Drug Profiles 274 Parkinson's Disease - Dormant Projects 797 Parkinson's Disease - Discontinued Products 822 Parkinson's Disease - Product Development Milestones 825 Appendix 839
List of Tables
Number of Products under Development for Parkinson's Disease, H2 2016 51 Number of Products under Development for Parkinson's Disease - Comparative Analysis, H2 2016 52 Number of Products under Development by Companies, H2 2016 53 Number of Products under Development by Companies, H2 2016 (Contd..1) 54 Number of Products under Development by Companies, H2 2016 (Contd..2) 55 Number of Products under Development by Companies, H2 2016 (Contd..3) 56 Number of Products under Development by Companies, H2 2016 (Contd..4) 57 Number of Products under Development by Companies, H2 2016 (Contd..5) 58 Number of Products under Development by Companies, H2 2016 (Contd..6) 59 Number of Products under Development by Companies, H2 2016 (Contd..7) 60 Number of Products under Development by Companies, H2 2016 (Contd..8) 61 Number of Products under Development by Companies, H2 2016 (Contd..9) 62 Number of Products under Development by Companies, H2 2016 (Contd..10) 63 Number of Products under Development by Companies, H2 2016 (Contd..11) 64 Number of Products under Development by Companies, H2 2016 (Contd..12) 65 Number of Products under Development by Companies, H2 2016 (Contd..13) 66 Number of Products under Development by Companies, H2 2016 (Contd..14) 67 Number of Products under Development by Companies, H2 2016 (Contd..15) 68 Number of Products under Investigation by Universities/Institutes, H2 2016 69 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 70 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 71 Comparative Analysis by Late Stage Development, H2 2016 72 Comparative Analysis by Clinical Stage Development, H2 2016 73 Comparative Analysis by Early Stage Development, H2 2016 74 Comparative Analysis by Unknown Stage Development, H2 2016 75 Products under Development by Companies, H2 2016 76 Products under Development by Companies, H2 2016 (Contd..1) 77 Products under Development by Companies, H2 2016 (Contd..2) 78 Products under Development by Companies, H2 2016 (Contd..3) 79 Products under Development by Companies, H2 2016 (Contd..4) 80 Products under Development by Companies, H2 2016 (Contd..5) 81 Products under Development by Companies, H2 2016 (Contd..6) 82 Products under Development by Companies, H2 2016 (Contd..7) 83 Products under Development by Companies, H2 2016 (Contd..8) 84 Products under Development by Companies, H2 2016 (Contd..9) 85 Products under Development by Companies, H2 2016 (Contd..10) 86 Products under Development by Companies, H2 2016 (Contd..11) 87 Products under Development by Companies, H2 2016 (Contd..12) 88 Products under Development by Companies, H2 2016 (Contd..13) 89 Products under Development by Companies, H2 2016 (Contd..14) 90 Products under Development by Companies, H2 2016 (Contd..15) 91 Products under Development by Companies, H2 2016 (Contd..16) 92 Products under Development by Companies, H2 2016 (Contd..17) 93 Products under Development by Companies, H2 2016 (Contd..18) 94 Products under Investigation by Universities/Institutes, H2 2016 95 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 96 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 97 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 98 Parkinson's Disease - Pipeline by 2-BBB Medicines BV, H2 2016 99 Parkinson's Disease - Pipeline by 4P Therapeutics LLC, H2 2016 100 Parkinson's Disease - Pipeline by AbbVie Inc, H2 2016 101 Parkinson's Disease - Pipeline by AC Immune SA, H2 2016 102 Parkinson's Disease - Pipeline by Acelot Inc, H2 2016 103 Parkinson's Disease - Pipeline by Acorda Therapeutics Inc, H2 2016 104 Parkinson's Disease - Pipeline by Adamas Pharmaceuticals Inc, H2 2016 105 Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H2 2016 106 Parkinson's Disease - Pipeline by Advinus Therapeutics Ltd, H2 2016 107 Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals Inc, H2 2016 108 Parkinson's Disease - Pipeline by AFFiRiS AG, H2 2016 109 Parkinson's Disease - Pipeline by Amabiotics SAS, H2 2016 110 Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H2 2016 111 Parkinson's Disease - Pipeline by American Gene Technologies International Inc, H2 2016 112 Parkinson's Disease - Pipeline by Anavex Life Sciences Corp, H2 2016 113 Parkinson's Disease - Pipeline by Angita BV, H2 2016 114 Parkinson's Disease - Pipeline by Antoxis Ltd, H2 2016 115 Parkinson's Disease - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2016 116 Parkinson's Disease - Pipeline by APeT Holding BV, H2 2016 117 Parkinson's Disease - Pipeline by ApoPharma Inc, H2 2016 118 Parkinson's Disease - Pipeline by Aposense Ltd, H2 2016 119 Parkinson's Disease - Pipeline by Araclon Biotech SL, H2 2016 120 Parkinson's Disease - Pipeline by ArmaGen Inc, H2 2016 121 Parkinson's Disease - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 122 Parkinson's Disease - Pipeline by AstraZeneca Plc, H2 2016 123 Parkinson's Disease - Pipeline by AudioCure Pharma GmbH, H2 2016 124 Parkinson's Disease - Pipeline by Berg LLC, H2 2016 125 Parkinson's Disease - Pipeline by Bial - Portela & Ca SA, H2 2016 126 Parkinson's Disease - Pipeline by Bio-Modeling Systems SAS, H2 2016 127 Parkinson's Disease - Pipeline by BioArtic AB, H2 2016 128 Parkinson's Disease - Pipeline by Biogen Inc, H2 2016 129 Parkinson's Disease - Pipeline by BioHealthonomics Inc, H2 2016 130 Parkinson's Disease - Pipeline by Biopharm GmbH, H2 2016 131 Parkinson's Disease - Pipeline by Biotie Therapies Corp, H2 2016 132 Parkinson's Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 133 Parkinson's Disease - Pipeline by Calico LLC, H2 2016 134 Parkinson's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H2 2016 135 Parkinson's Disease - Pipeline by Cardax Inc, H2 2016 136 Parkinson's Disease - Pipeline by Carna Biosciences Inc, H2 2016 137 Parkinson's Disease - Pipeline by Cell Cure Neurosciences Ltd, H2 2016 138 Parkinson's Disease - Pipeline by Cellceutix Corp, H2 2016 139 Parkinson's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H2 2016 140 Parkinson's Disease - Pipeline by Chipscreen Biosciences Ltd, H2 2016 141 Parkinson's Disease - Pipeline by Clera Inc, H2 2016 142 Parkinson's Disease - Pipeline by Clevexel Pharma SA, H2 2016 143 Parkinson's Disease - Pipeline by Contera Pharma ApS, H2 2016 144 Parkinson's Disease - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 145 Parkinson's Disease - Pipeline by Corium International Inc, H2 2016 146 Parkinson's Disease - Pipeline by Curemark LLC, H2 2016 147 Parkinson's Disease - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 148 Parkinson's Disease - Pipeline by Denali Therapeutics Inc, H2 2016 149 Parkinson's Disease - Pipeline by Depomed Inc, H2 2016 150 Parkinson's Disease - Pipeline by DermaXon LLC, H2 2016 151 Parkinson's Disease - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 152 Parkinson's Disease - Pipeline by Dizlin Medical Design AB, H2 2016 153 Parkinson's Disease - Pipeline by Domain Therapeutics SA, H2 2016 154 Parkinson's Disease - Pipeline by Edison Pharmaceuticals Inc, H2 2016 155 Parkinson's Disease - Pipeline by Eli Lilly and Company, H2 2016 156 Parkinson's Disease - Pipeline by Ensemble Therapeutics Corp, H2 2016 157 Parkinson's Disease - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2016 158 Parkinson's Disease - Pipeline by FPRT Bio Inc, H2 2016 159 Parkinson's Disease - Pipeline by Genecode AS, H2 2016 160 Parkinson's Disease - Pipeline by Generon (Shanghai) Corp Ltd, H2 2016 161 Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 162 Parkinson's Disease - Pipeline by GenKyoTex SA, H2 2016 163 Parkinson's Disease - Pipeline by Genmab A/S, H2 2016 164 Parkinson's Disease - Pipeline by Genosco Inc, H2 2016 165 Parkinson's Disease - Pipeline by Genzyme Corp, H2 2016 166 Parkinson's Disease - Pipeline by H. Lundbeck A/S, H2 2016 167 Parkinson's Disease - Pipeline by Harbor Therapeutics Inc, H2 2016 168 Parkinson's Disease - Pipeline by Heptares Therapeutics Ltd, H2 2016 169 Parkinson's Disease - Pipeline by Herantis Pharma Plc, H2 2016 170 Parkinson's Disease - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2016 171 Parkinson's Disease - Pipeline by Horizon Pharma Plc, H2 2016 172 Parkinson's Disease - Pipeline by Huons Co Ltd, H2 2016 173 Parkinson's Disease - Pipeline by ICB International Inc, H2 2016 174 Parkinson's Disease - Pipeline by Immungenetics AG, H2 2016 175 Parkinson's Disease - Pipeline by Impel NeuroPharma Inc, H2 2016 176 Parkinson's Disease - Pipeline by Intec Pharma ltd, H2 2016 177 Parkinson's Disease - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 178 Parkinson's Disease - Pipeline by InterMed Discovery GmbH, H2 2016 179 Parkinson's Disease - Pipeline by International Stem Cell Corp, H2 2016 180 Parkinson's Disease - Pipeline by Io Therapeutics Inc, H2 2016 181 Parkinson's Disease - Pipeline by Iproteos SL, H2 2016 182 Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 183 Parkinson's Disease - Pipeline by Kainos Medicine Inc, H2 2016 184 Parkinson's Disease - Pipeline by Khondrion BV, H2 2016 185 Parkinson's Disease - Pipeline by KineMed Inc, H2 2016 186 Parkinson's Disease - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2016 187 Parkinson's Disease - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 188 Parkinson's Disease - Pipeline by Lead Discovery Center GmbH, H2 2016 189 Parkinson's Disease - Pipeline by Living Cell Technologies Ltd, H2 2016 190 Parkinson's Disease - Pipeline by Longevity Biotech Inc, H2 2016 191 Parkinson's Disease - Pipeline by Luye Pharma Group Ltd, H2 2016 192 Parkinson's Disease - Pipeline by Lysosomal Therapeutics Inc, H2 2016 193 Parkinson's Disease - Pipeline by M et P Pharma AG, H2 2016 194 Parkinson's Disease - Pipeline by M's Science Corp, H2 2016 195 Parkinson's Disease - Pipeline by M3 Biotechnology Inc, H2 2016 196 Parkinson's Disease - Pipeline by MedGenesis Therapeutix Inc, H2 2016 197 Parkinson's Disease - Pipeline by MedImmune LLC, H2 2016 198 Parkinson's Disease - Pipeline by MeiraGTx Ltd, H2 2016 199 Parkinson's Disease - Pipeline by Merck & Co Inc, H2 2016 200 Parkinson's Disease - Pipeline by Metabolic Solutions Development Company LLC, H2 2016 201 Parkinson's Disease - Pipeline by Minerva Neurosciences Inc, H2 2016 202 Parkinson's Disease - Pipeline by Mission Therapeutics Ltd, H2 2016 203 Parkinson's Disease - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 204 Parkinson's Disease - Pipeline by MitoDys Therapeutics Ltd, H2 2016 205 Parkinson's Disease - Pipeline by Motac Neuroscience Ltd, H2 2016 206 Parkinson's Disease - Pipeline by Netherlands Translational Research Center BV, H2 2016 207 Parkinson's Disease - Pipeline by Neuralstem Inc, H2 2016 208 Parkinson's Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2016 209 Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Ltd, H2 2016 210 Parkinson's Disease - Pipeline by NeuroDerm Ltd, H2 2016 211 Parkinson's Disease - Pipeline by NeuroNascent Inc, H2 2016 212 Parkinson's Disease - Pipeline by NeurOp Inc, H2 2016 213 Parkinson's Disease - Pipeline by Neuropore Therapies Inc, H2 2016 214 Parkinson's Disease - Pipeline by New World Laboratories Inc, H2 2016 215 Parkinson's Disease - Pipeline by Newron Pharmaceuticals SpA, H2 2016 216 Parkinson's Disease - Pipeline by nLife Therapeutics SL, H2 2016 217 Parkinson's Disease - Pipeline by NLS Pharma Group, H2 2016 218 Parkinson's Disease - Pipeline by Novartis AG, H2 2016 219 Parkinson's Disease - Pipeline by Novo Nordisk A/S, H2 2016 220 Parkinson's Disease - Pipeline by NsGene A/S, H2 2016 221 Parkinson's Disease - Pipeline by Omeros Corp, H2 2016 222 Parkinson's Disease - Pipeline by Oncodesign SA, H2 2016 223 Parkinson's Disease - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 224 Parkinson's Disease - Pipeline by OPKO Health Inc, H2 2016 225 Parkinson's Disease - Pipeline by Orion Oyj, H2 2016 226 Parkinson's Disease - Pipeline by Oryzon Genomics SA, H2 2016 227 Parkinson's Disease - Pipeline by Oxford BioMedica Plc, H2 2016 228 Parkinson's Disease - Pipeline by ParkCell AB, H2 2016 229 Parkinson's Disease - Pipeline by Peptron Inc, H2 2016 230 Parkinson's Disease - Pipeline by Pfizer Inc, H2 2016 231 Parkinson's Disease - Pipeline by Pharma Two B Ltd, H2 2016 232 Parkinson's Disease - Pipeline by PharmatrophiX Inc, H2 2016 233 Parkinson's Disease - Pipeline by Pharmaxis Ltd, H2 2016 234 Parkinson's Disease - Pipeline by Pharmicell Co Ltd, H2 2016 235 Parkinson's Disease - Pipeline by Pharnext SA, H2 2016 236 Parkinson's Disease - Pipeline by Phenomenome Discoveries Inc, H2 2016 237 Parkinson's Disease - Pipeline by Plex Pharmaceuticals Inc, H2 2016 238 Parkinson's Disease - Pipeline by Prana Biotechnology Ltd, H2 2016 239 Parkinson's Disease - Pipeline by Prexton Therapeutics SA, H2 2016 240 Parkinson's Disease - Pipeline by Primary Peptides Inc, H2 2016 241 Parkinson's Disease - Pipeline by Proclara Biosciences Inc, H2 2016 242 Parkinson's Disease - Pipeline by Promentis Pharmaceuticals Inc, H2 2016 243 Parkinson's Disease - Pipeline by Promius Pharma LLC, H2 2016 244 Parkinson's Disease - Pipeline by Proteostasis Therapeutics Inc, H2 2016 245 Parkinson's Disease - Pipeline by Prothena Corp Plc, H2 2016 246 Parkinson's Disease - Pipeline by QR Pharma Inc, H2 2016 247 Parkinson's Disease - Pipeline by reMYND NV, H2 2016 248 Parkinson's Disease - Pipeline by Retrotope Inc, H2 2016 249 Parkinson's Disease - Pipeline by Sage Therapeutics Inc, H2 2016 250 Parkinson's Disease - Pipeline by Saje Pharma LLC, H2 2016 251 Parkinson's Disease - Pipeline by SanBio Inc, H2 2016 252 Parkinson's Disease - Pipeline by Saneron CCEL Therapeutics Inc, H2 2016 253 Parkinson's Disease - Pipeline by Saniona AB, H2 2016 254 Parkinson's Disease - Pipeline by Sellas Inc, H2 2016 255 Parkinson's Disease - Pipeline by Serina Therapeutics Inc, H2 2016 256 Parkinson's Disease - Pipeline by Shire Plc, H2 2016 257 Parkinson's Disease - Pipeline by Sigma-Tau SpA, H2 2016 258 Parkinson's Disease - Pipeline by SignPath Pharma Inc, H2 2016 259 Parkinson's Disease - Pipeline by Signum Biosciences Inc, H2 2016 260 Parkinson's Disease - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 261 Parkinson's Disease - Pipeline by STATegics Inc, H2 2016 262 Parkinson's Disease - Pipeline by Stelic Institute & Co Inc, H2 2016 263 Parkinson's Disease - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 264 Parkinson's Disease - Pipeline by Sunovion Pharmaceuticals Inc, H2 2016 265 Parkinson's Disease - Pipeline by Synthonics Inc, H2 2016 266 Parkinson's Disease - Pipeline by Takara Bio Inc, H2 2016 267 Parkinson's Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 268 Parkinson's Disease - Pipeline by TauRx Therapeutics Ltd, H2 2016 269 Parkinson's Disease - Pipeline by TechnoPhage SA, H2 2016 270 Parkinson's Disease - Pipeline by Teikoku Pharma USA Inc, H2 2016 271 Parkinson's Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 272 Parkinson's Disease - Pipeline by Titan Pharmaceuticals Inc, H2 2016 273 Parkinson's Disease - Pipeline by Trevena Inc, H2 2016 274 Parkinson's Disease - Pipeline by TyrNovo Ltd, H2 2016 275 Parkinson's Disease - Pipeline by UniQure NV, H2 2016 276 Parkinson's Disease - Pipeline by Vanton Research Laboratory LLC, H2 2016 277 Parkinson's Disease - Pipeline by Varinel Inc, H2 2016 278 Parkinson's Disease - Pipeline by VistaGen Therapeutics Inc, H2 2016 279 Parkinson's Disease - Pipeline by VivaCell Biotechnology Espana SL, H2 2016 280 Parkinson's Disease - Pipeline by Voyager Therapeutics Inc, H2 2016 281 Parkinson's Disease - Pipeline by vTv Therapeutics Inc, H2 2016 282 Parkinson's Disease - Pipeline by Wellstat Therapeutics Corp, H2 2016 283 Assessment by Monotherapy Products, H2 2016 284 Assessment by Combination Products, H2 2016 285 Number of Products by Stage and Target, H2 2016 287 Number of Products by Stage and Mechanism of Action, H2 2016 298 Number of Products by Stage and Route of Administration, H2 2016 310 Number of Products by Stage and Molecule Type, H2 2016 312 Parkinson's Disease - Dormant Projects, H2 2016 836 Parkinson's Disease - Dormant Projects (Contd..1), H2 2016 837 Parkinson's Disease - Dormant Projects (Contd..2), H2 2016 838 Parkinson's Disease - Dormant Projects (Contd..3), H2 2016 839 Parkinson's Disease - Dormant Projects (Contd..4), H2 2016 840 Parkinson's Disease - Dormant Projects (Contd..5), H2 2016 841 Parkinson's Disease - Dormant Projects (Contd..6), H2 2016 842 Parkinson's Disease - Dormant Projects (Contd..7), H2 2016 843 Parkinson's Disease - Dormant Projects (Contd..8), H2 2016 844 Parkinson's Disease - Dormant Projects (Contd..9), H2 2016 845 Parkinson's Disease - Dormant Projects (Contd..10), H2 2016 846 Parkinson's Disease - Dormant Projects (Contd..11), H2 2016 847 Parkinson's Disease - Dormant Projects (Contd..12), H2 2016 848 Parkinson's Disease - Dormant Projects (Contd..13), H2 2016 849 Parkinson's Disease - Dormant Projects (Contd..14), H2 2016 850 Parkinson's Disease - Dormant Projects (Contd..15), H2 2016 851 Parkinson's Disease - Dormant Projects (Contd..16), H2 2016 852 Parkinson's Disease - Dormant Projects (Contd..17), H2 2016 853 Parkinson's Disease - Dormant Projects (Contd..18), H2 2016 854 Parkinson's Disease - Dormant Projects (Contd..19), H2 2016 855 Parkinson's Disease - Dormant Projects (Contd..20), H2 2016 856 Parkinson's Disease - Dormant Projects (Contd..21), H2 2016 857 Parkinson's Disease - Dormant Projects (Contd..22), H2 2016 858 Parkinson's Disease - Dormant Projects (Contd..23), H2 2016 859 Parkinson's Disease - Dormant Projects (Contd..24), H2 2016 860 Parkinson's Disease - Discontinued Products, H2 2016 861 Parkinson's Disease - Discontinued Products (Contd..1), H2 2016 862 Parkinson's Disease - Discontinued Products (Contd..2), H2 2016 863



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2500
Multi User - US $5000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify